Company / PP&E (Net)
Cue Biopharma, Inc. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$241.0K
FY2025
5-year range
$241.0K / $2.1M
FY2021-FY2025
Trend
-48.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 4 consecutive years, from $2M in FY2021 to $241,000 in FY2025.
Based on SEC 10-K filings.
$241,000 in FY2025 with a 5-year CAGR of -35.2%.
Declined from $795,000 to $241,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -45.6%
- 5-Year CAGR
- -35.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- Cue Biopharma, Inc.'s pp&e (net) has declined for 4 consecutive years.
- 5-year CAGR of -35.2%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 48.8% year-over-year.
- Peak pp&e (net) was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $241.0K | -48.8% |
| FY2024 | $471.0K | -40.8% |
| FY2023 | $795.0K | -47.0% |
| FY2022 | $1.5M | -29.0% |
| FY2021 | $2.1M | +0.2% |
| FY2020 | $2.1M | +14.1% |
| FY2019 | $1.8M | -33.6% |
| FY2018 | $2.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026